SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 2

Conditions: Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell

Treatments: Drug: SCH 727965; Drug: Bortezomib; Biological: Alemtuzumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00871546

P04715

Details and patient eligibility

About

Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]). Part 1 of the study will determine the activity of SCH 727965 treatment in participants with MCL and participants with B-CLL. Part 2 of the study will determine the activity of SCH 727965 treatment in participants who experienced disease progression after standard treatment with the comparator drug during Part 1.

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >=18 years, either sex, any race.

• Eastern Cooperative Oncology group performance status of 0 or 1.

• Adequate hematologic, renal, and hepatic organ function and laboratory parameters.

• For subjects with MCL:

  • Diagnosis of MCL according to the World Health Organization (WHO) criteria.
  • Received at least one prior chemotherapeutic regimen, but no more than two regimens including stem cell transplantation..
  • Measurable or assessable disease by the Revised Response Criteria for Malignant Lymphoma.

• For subjects with B-CLL

  • Documented B-CLL according to the National Cancer Institute Working Group (NCI-WG) criteria.
  • Received at least one prior alkylating agent-based regimen and one fludarabine- or pentostatin-containing regimen, but must not have received more than two prior regimens.
  • Measurable or assessable disease by NCI-WG criteria.

Exclusion criteria

• Known central nervous system involvement of MCL or B-CLL.
• Previous treatment with SCH 727965 or other cyclin-dependent kinase inhibitors.
• For MCL, previous treatment with bortezomib.
• For B-CLL, previous treatment with alemtuzumab.
• Known HIV infection.
• Known active hepatitis B or C.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

8 participants in 6 patient groups

Participants with MCL randomized to SCH 727965

Experimental group

Treatment:

Drug: SCH 727965

Participants with MCL randomized to bortezomib

Active Comparator group

Treatment:

Drug: Bortezomib

MCL treated w/SCH 727965 after progression on bortezomib

Experimental group

Treatment:

Drug: SCH 727965

Participants with B-CLL randomized to SCH 727965

Experimental group

Treatment:

Drug: SCH 727965

Participants with B-CLL randomized to alemtuzumab

Active Comparator group

Treatment:

Biological: Alemtuzumab

B-CLL treated w/ SCH 727965 after progression on alemtuzumab

Experimental group

Treatment:

Drug: SCH 727965